Desglymidodrine

Desglymidodrine
Clinical data
Other namesDeglymidodrine; ST-1059; 3,6-Dimethoxy-β-hydroxy-2-phenylethylamine
Drug classα1-Adrenergic receptor agonist; Antihypotensive agent; Vasopressor
Identifiers
  • 2-amino-1-(2,5-dimethoxyphenyl)ethanol
CAS Number
PubChem CID
DrugBank
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.322.299 Edit this at Wikidata
Chemical and physical data
FormulaC10H15NO3
Molar mass197.234 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1)OC)C(CN)O
  • InChI=1S/C10H15NO3/c1-13-7-3-4-10(14-2)8(5-7)9(12)6-11/h3-5,9,12H,6,11H2,1-2H3
  • Key:VFRCNXKYZVQYLX-UHFFFAOYSA-N

Desglymidodrine (developmental code name ST-1059) is the active metabolite of the prodrug antihypotensive agent midodrine.[1][2][3] It acts as a selective α1-adrenergic receptor agonist.[1][2][3] Desglymidodrine is formed from midodrine via deglycination.[1][2][3]

  1. ^ a b c McClellan KJ, Wiseman LR, Wilde MI (January 1998). "Midodrine. A review of its therapeutic use in the management of orthostatic hypotension". Drugs & Aging. 12 (1): 76–86. doi:10.2165/00002512-199812010-00007. PMID 9467688.
  2. ^ a b c Cruz DN (May 2000). "Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension". Expert Opinion on Pharmacotherapy. 1 (4): 835–840. doi:10.1517/14656566.1.4.835. PMID 11249519.
  3. ^ a b c Gutman LB, Wilson BJ (August 2017). "The Role of Midodrine for Hypotension Outside of the Intensive Care Unit". Journal of Population Therapeutics and Clinical Pharmacology = Journal de la Therapeutique des Populations et de la Pharmacologie Clinique. 24 (3): e45–e50. doi:10.22374/1710-6222.24.3.4 (inactive 1 November 2024). PMID 28873293.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)